Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891913 | 0.84 | PDPK1 (0.39) | SLC6A2SLC6A4SLC6A3ABCB11 | |
| SCHEMBL25833165 | 0.79 | PARP1 (0.42) | SLC6A2SLC6A4SLC6A3ABCB11 | |
| SCHEMBL19069421 | 0.79 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17071856 | 0.79 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16770633 | 0.79 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16770677 | 0.77 | SLC6A4 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16770784 | 0.77 | SLC6A4 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25833224 | 0.76 | AOC3 (0.33) | — | |
| SCHEMBL19121496 | 0.75 | LMNA (0.40) | — | |
| SCHEMBL6058476 | 0.74 | L3MBTL1 (0.38) | SLC6A2SLC6A4SLC6A3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | SLC6A2 1803/4885SLC6A4 2807/4885SLC6A3 1676/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | SLC6A2 1803/4885SLC6A4 2807/4885SLC6A3 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.